Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)
ID: 345748Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $200K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345748

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAS-23-086.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK," aimed at supporting pilot and feasibility clinical trials related to diabetes, kidney diseases, and digestive disorders. This initiative encourages the submission of small, short-term proof-of-concept trials that gather preliminary data on interventions, with a focus on enhancing understanding and treatment of these diseases without the need for extensive prior data. The program is designed to foster innovation in clinical research by enabling smaller studies to navigate regulatory and financial barriers, ultimately contributing to improved health outcomes. The total funding commitment for fiscal year 2024 is $1 million, with individual project budgets capped at $200,000 per year for a maximum of three years. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with a submission deadline of May 7, 2026.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAS-23-086-Full-Announcement.html
    PAS-23-086.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a funding opportunity titled "Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK." This initiative encourages pilot and feasibility clinical trials aiming to advance larger clinical studies related to diabetes, kidney diseases, and digestive disorders. The funding aims to support short-term proof-of-concept trials that gather preliminary data on interventions without requiring extensive prior data. Key details include a funding commitment of $1 million for fiscal year 2024, limited budget allocations of $200,000 per year for a maximum project period of three years, and eligibility extending to various institutions and organizations. Applicants are encouraged to involve diverse populations to address health disparities. Strict guidelines are set regarding submission, including the utilization of new NIH application forms and adherence to data management mandates. The program's goal is to foster innovation in clinical research by enabling smaller studies to overcome regulatory and financial barriers while contributing to improved health outcomes in targeted diseases. Overall, this funding opportunity aims to strengthen the clinical trial pipeline with a focus on intervention impact and public health implications.
    Similar Opportunities
    Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)." This grant aims to support translational research that justifies later-phase therapeutic discovery and development efforts related to diseases such as obesity, diabetes, digestive disorders, and kidney diseases. The initiative encourages innovative research on novel small molecules and biologics, with a focus on therapeutics that significantly improve or differentiate from existing treatments. NIH anticipates awarding 3-4 grants annually, with budgets ranging from $250,000 to $300,000 per project for up to five years. Interested applicants must submit their proposals by January 7, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. Additional details can be found at http://grants.nih.gov/grants/guide/pa-files/PAR-22-111.html.
    NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed) to support pioneering biomedical research focused on critical scientific challenges related to diabetes, digestive diseases, and kidney diseases. This grant aims to fund individual scientists proposing innovative and high-impact studies that diverge from their existing research, encouraging bold ideas and unconventional hypotheses within the domains of the Division of Diabetes, Endocrinology and Metabolic Diseases and the Division of Digestive Diseases and Nutrition. The award has a budget ceiling of $500,000 per year for a maximum project period of five years, with a total funding commitment of $4.8 million for FY 2026 to support up to six awards. Interested applicants must adhere to NIH registration requirements and submit their proposals by July 18, 2025, with further inquiries directed to grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Impact, Interdisciplinary Science in NIDDK Research Areas" (PAR-25-277) aimed at supporting innovative research that addresses critical knowledge gaps in diabetes, digestive, and kidney diseases. This grant program encourages interdisciplinary approaches to foster discovery-based science and develop transformative technologies that can significantly impact the broader scientific community. Eligible applicants include a wide range of organizations, such as higher education institutions and nonprofits, with proposals accepted for projects lasting up to five years. Interested parties should ensure compliance with application guidelines and submit their proposals by the deadline of October 15, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-277.html.
    NIDDK Education Program Grants (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering Research Education Program Grants (R25) to enhance training in biomedical, behavioral, and clinical research. This funding opportunity aims to support educational activities that develop research skills and provide hands-on experiences in areas critical to NIDDK, including diabetes, digestive diseases, and obesity. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and local governments, with a funding limit of $100,000 per year for up to five years. The application deadline is January 30, 2024, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-074.html.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has announced a Limited Competition Small Grant Program aimed at supporting current K01, K08, K23, and K25 award recipients. This program is designed to facilitate the transition of these early-career researchers to fully independent investigator status by providing funding for small, self-contained research projects, with grants offering up to $75,000 in direct costs per year for a maximum project period of two years. The initiative encourages applicants to demonstrate their growing independence and ability to secure future funding, particularly for R01 applications, while adhering to NIH policies regarding human subjects and clinical trials. Interested applicants must submit their proposals by September 7, 2025, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" aimed at supporting preclinical efficacy studies for therapeutic agents targeting rare diseases. This initiative seeks to fund projects that demonstrate the effectiveness of proposed treatments in established rare disease models, along with necessary pharmacodynamic and pharmacokinetic studies, to facilitate further development towards Investigational New Drug (IND) applications or clinical trials. With a total funding budget of up to $1.2 million, the NIH anticipates awarding 3-5 grants, each with a maximum budget of $275,000 over a two-year project period. Interested applicants must submit letters of intent by May 1, 2024, with full applications due by May 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.